/PRNewswire/ New findings demonstrate the clinical efficacy of AI-powered tissue analysis as a guide in cancer treatment, according to medical AI provider.
/PRNewswire/ Lunit today announced the presentation of 11 abstracts featuring its AI-biomarker platform at the 2022 ASCO Annual Meeting from June 3 to 7..
First CE Mark for Lunit AI-powered pathology solutionLunit to focus on launching 'Lunit SCOPE PD-L1' in Europe within the second half of 2022SEOUL, South Korea, April 27, 2022 /PRNewswire/
/PRNewswire/ Lunit, a leading medical AI provider, announced today a preliminary approval from the Korea Exchange for initial public offering (IPO) on the.
/PRNewswire/ Lunit, a leading startup in AI-based cancer solutions, announced today the publication of its study in the Journal of Clinical Oncology (JCO)..